Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...
Findings from a literature review recently published in The American Journal of Public Health suggest that greater ...
During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...
Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback